Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Primary Objective:
To assess the efficacy of SAR292833 versus placebo in reducing pain intensity associated with chronic peripheral neuropathic pain using 11-point numerical rating scale (NRS).
Secondary Objectives:
To compare the effects of SAR292833 with placebo on the change of neuropathic pain symptoms versus baseline Neuropathic Pain Symptoms Inventory (NPSI);
To evaluate the effects of SAR292833 in comparison to placebo on the change in pain intensity of mechanical allodynia;
To investigate the safety and tolerability of SAR292833 in comparison to placebo;
To investigate the pharmacokinetics (PK) and the relationships between main efficacy parameters or pharmacodynamic effect (PD) and pharmacokinetics (PK/PD) of SAR292833 in patients with chronic peripheral neuropathic pain.
MULTINATIONAL, MULTICENTER, RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF EFFICACY AND SAFETY OF SAR292833 ADMINISTRATION FOR 4 WEEKS IN PATIENTS WITH CHRONIC PERIPHERAL NEUROPATHIC PAIN - ALCHEMILLA
100 项与 GRC-15300 相关的专利(医药)